Related Experiment Video
Updated: Jan 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm With De Novo TET2 and KDM6A Mutations
Zixin Qiu1, Jianbo Tong1, Chuan Wan1
1Department of Dermatology, the 1st Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
None:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematologic malignancy characterized by cutaneous involvement with potential dissemination to peripheral blood, bone marrow, lymph nodes, or extranodal sites. We present the first documented case of BPDCN exhibiting complex epigenetic dysregulation in a 54-year-old female who developed rapidly progressive purpuric lesions on the trunk, diagnosed via skin biopsy and immunohistochemistry. Cytogenetic analysis revealed triple molecular aberrations including a t(1;6) (p31;q25) translocation, a TET2 frameshift deletion (44.1% VAF), and a KDM6A missense mutation (c.262G>A, 46.6% VAF). The patient died within 6 months post-diagnosis, suggesting that this aggressive clinical course may be associated with a novel clinicogenetic subtype of BPDCN.

